← All trials
NCT00000478
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 1990
- Primary completion
- —
- Completion date
- Jun 1, 1997
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- St. Louis UniversityOfficial
- University of OttawaOfficial
- Johns Hopkins UniversityOfficial
- University of FloridaOfficial
- Harvard UniversityOfficial
- Yeshiva UniversityOfficial
- University of LondonOfficial
- Baylor UniversityOfficial
- Henry Ford Health SystemOfficial
- University of Alabama, BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.